1/13
09:02 am
orka
Oruka Therapeutics (NASDAQ:ORKA) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock, up previously from $42.00.
Low
Report
Oruka Therapeutics (NASDAQ:ORKA) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock, up previously from $42.00.
1/12
11:29 am
orka
Oruka Therapeutics (NASDAQ:ORKA) had its price target raised by analysts at BTIG Research from $63.00 to $73.00. They now have a "buy" rating on the stock.
Medium
Report
Oruka Therapeutics (NASDAQ:ORKA) had its price target raised by analysts at BTIG Research from $63.00 to $73.00. They now have a "buy" rating on the stock.
1/12
07:20 am
orka
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 [Yahoo! Finance]
Medium
Report
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 [Yahoo! Finance]
1/12
07:00 am
orka
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
High
Report
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
1/9
06:10 am
orka
Oruka Therapeutics (NASDAQ:ORKA) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Medium
Report
Oruka Therapeutics (NASDAQ:ORKA) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
1/7
02:01 am
orka
Oruka Therapeutics (NASDAQ:ORKA) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Medium
Report
Oruka Therapeutics (NASDAQ:ORKA) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
1/6
07:00 am
orka
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/5
10:16 pm
orka
Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears [Seeking Alpha]
Low
Report
Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears [Seeking Alpha]
12/19
05:58 am
orka
Oruka Therapeutics (NASDAQ:ORKA) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
High
Report
Oruka Therapeutics (NASDAQ:ORKA) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
12/18
07:11 am
orka
Oruka Therapeutics (NASDAQ:ORKA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Low
Report
Oruka Therapeutics (NASDAQ:ORKA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
12/11
04:47 pm
orka
Oruka Therapeutics Announces New Board Member and Board Transition [Yahoo! Finance]
Low
Report
Oruka Therapeutics Announces New Board Member and Board Transition [Yahoo! Finance]
12/11
04:01 pm
orka
Oruka Therapeutics Announces New Board Member and Board Transition
Low
Report
Oruka Therapeutics Announces New Board Member and Board Transition
11/16
01:06 am
orka
Oruka Therapeutics (NASDAQ:ORKA) was downgraded by analysts at
Wall Stre
Low
Report
Oruka Therapeutics (NASDAQ:ORKA) was downgraded by analysts at
Wall Stre
11/15
04:40 am
orka
ORKA-001 Trial Progress and US$180 Million PIPE Financing Might Change The Case For Investing In Oruka Therapeutics (ORKA) [Yahoo! Finance]
Low
Report
ORKA-001 Trial Progress and US$180 Million PIPE Financing Might Change The Case For Investing In Oruka Therapeutics (ORKA) [Yahoo! Finance]
11/13
08:11 am
orka
Oruka Therapeutics (NASDAQ:ORKA) had its price target raised by analysts at BTIG Research from $56.00 to $63.00. They now have a "buy" rating on the stock.
Medium
Report
Oruka Therapeutics (NASDAQ:ORKA) had its price target raised by analysts at BTIG Research from $56.00 to $63.00. They now have a "buy" rating on the stock.
11/13
08:11 am
orka
Oruka Therapeutics (NASDAQ:ORKA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $45.00 price target on the stock.
Medium
Report
Oruka Therapeutics (NASDAQ:ORKA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $45.00 price target on the stock.
11/13
12:43 am
orka
Oruka Therapeutics GAAP EPS of -$0.55 beats by $0.01 [Seeking Alpha]
Medium
Report
Oruka Therapeutics GAAP EPS of -$0.55 beats by $0.01 [Seeking Alpha]
11/12
04:53 pm
orka
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/12
04:05 pm
orka
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/29
07:00 am
orka
Oruka Therapeutics to Present at Multiple November Investor Conferences
Low
Report
Oruka Therapeutics to Present at Multiple November Investor Conferences
10/27
08:06 am
orka
Oruka Therapeutics (NASDAQ:ORKA) is now covered by analysts at Guggenheim. They set a "buy" rating and a $60.00 price target on the stock.
Medium
Report
Oruka Therapeutics (NASDAQ:ORKA) is now covered by analysts at Guggenheim. They set a "buy" rating and a $60.00 price target on the stock.
10/27
08:05 am
orka
Oruka Therapeutics (NASDAQ:ORKA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock, down previously from $45.00.
Medium
Report
Oruka Therapeutics (NASDAQ:ORKA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock, down previously from $45.00.